SCHEMBL13250526

SCHEMBL13250526

Brc1ccc(C(c2cccc(CN3CCCNCc4cccc(c4)CNCCC3)c2)c2cccc(CN3CCCNCc4cccc(c4)CNCCC3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ GAA P10253 1/20 0.39
▸ CXCR4 P61073 7/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PRMT6 Q96LA8 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ ADRA2C P18825 1/20 0.36
▸ CCR2 P41597 1/20 0.36
▸ CXCL12 P48061 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ GPR183 P32249 1/20 0.36
▸ MBTD1 Q05BQ5 1/20 0.36
▸ L3MBTL3 Q96JM7 1/20 0.36
▸ ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250545 0.92 CXCR4 (0.48) SMN1; SMN2TDP1CXCR4IGF1RALDH1A1
SCHEMBL13250519 0.91 CXCR4 (0.43) SMN1; SMN2TDP1CXCR4ALDH1A1PRMT6
SCHEMBL13250527 0.89 ALDH1A1 (0.47) SMN1; SMN2TDP1GAACXCR4ALDH1A1
SCHEMBL13250522 0.89 CXCR4 (0.46) SMN1; SMN2TDP1GAACXCR4ALDH1A1
SCHEMBL13250533 0.87 CXCR4 (0.51) SMN1; SMN2TDP1GAACXCR4IGF1R
SCHEMBL13250493 0.86 CXCR4 (0.53) SMN1; SMN2TDP1CXCR4IGF1RMEN1
SCHEMBL13250528 0.85 CXCR4 (0.47) SMN1; SMN2TDP1GAACXCR4ALDH1A1
SCHEMBL13250543 0.85 CXCR4 (0.50) TDP1CXCR4MEN1CHRM2CHRM1
SCHEMBL13250547 0.83 CXCR4 (0.50) TDP1CXCR4MEN1CHRM2CHRM1
SCHEMBL13250544 0.81 CXCR4 (0.55) SMN1; SMN2TDP1GAACXCR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS SMN1; SMN2 2611/4885TDP1 1911/4885GAA 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback